Inflammatory cytokines participate in the pathology of epilepsy and the development of drug resistance. In this study, we combined a cytokine array and enzyme-linked immunosorbent assay to identify new cytokines in the plasma from children on early stage of the onset of epilepsy (EOE) and children with drug-resistant epilepsy (DRE). Compared with healthy controls, a broad up-regulation of cytokines was observed in patients with EOE, and many of the cytokines were not previously reported. In patients with DRE, most of these up-regulated cytokines maintained at relatively low levels close to those in controls; only a few of them, including CCL5, Serpin E1, and IGFBP2, remained at high levels. The dramatic difference in cytokine profile could be a strong clue for the incidence of DRE, and DRE-associated cytokines appeared to have the potential to be new biomarkers for epilepsy prognosis and therapeutic targets.
FisherRSvan Emde BoasWBlumeW, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46(4):470-472. doi:10.1111/j.0013-9580.2005.66104.x.
2.
ThijsRDSurgesRO’BrienTJSanderJW.Epilepsy in adults. Lancet. 2019;393(10172):689-701. doi:10.1016/S0140-6736(18)32596-0.
LöscherWPotschkaHSisodiyaSMVezzaniA.Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72(3):606-638. doi:10.1124/pr.120.019539.
5.
KwanPArzimanoglouABergAT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51(6):1069-1077. doi:10.1111/j.1528-1167.2009.02397.x.
6.
ChenYNagibMMYasmenN, et al. Neuroinflammatory mediators in acquired epilepsy: an update. Inflamm Res. 2023;72:683-701. doi:10.1007/s00011-023-01700-8.
7.
FabenePFBramantiPConstantinG.The emerging role for chemokines in epilepsy. J Neuroimmunol. 2010;224(1-2):22-27. doi:10.1016/j.jneuroim.2010.05.016.
8.
JanigroD.Are you in or out? Leukocyte, ion, and neurotransmitter permeability across the epileptic blood-brain barrier. Epilepsia. 2012;53(01)(Suppl1):26-34. doi:10.1111/j.1528-1167.2012.03472.x.
9.
Campos-BedollaPFeria-RomeroIOrozco-SuárezS.Factors not considered in the study of drug-resistant epilepsy: drug-resistant epilepsy: assessment of neuroinflammation. Epilepsia Open. 2022;7(suppl 1):S68-S80. doi:10.1002/epi4.12590.
10.
JankowskyJLPattersonPH.The role of cytokines and growth factors in seizures and their sequelae. Prog Neurobiol. 2001;63(2):125-149. doi:10.1016/s0301-0082(00)00022-8.
11.
KanAAde JagerWde WitM, et al. Protein expression profiling of inflammatory mediators in human temporal lobe epilepsy reveals co-activation of multiple chemokines and cytokines. J Neuroinflammation. 2012;9:207. doi:10.1186/1742-2094-9-207.
12.
MaoLYDingJPengWF, et al. Interictal interleukin-17A levels are elevated and correlate with seizure severity of epilepsy patients. Epilepsia. 2013;54(9):e142-145. doi:10.1111/epi.12337.
13.
ZhangHTanJZLuoJWangW.Chitinase-3-like protein 1 may be a potential biomarker in patients with drug-resistant epilepsy. Neurochem Int. 2019;124:62-67. doi:10.1016/j.neuint.2018.12.013.
14.
SeinoM.Classification criteria of epileptic seizures and syndromes. Epilepsy Res. 2006;70(suppl 1):S27-S33. doi:10.1016/j.eplepsyres.2006.01.016.
15.
SimonatoMAgostonDVBrooks-KayalA, et al. Identification of clinically relevant biomarkers of epileptogenesis—a strategic roadmap. Nat Rev Neurol. 2021;17(4):231-242. doi:10.1038/s41582-021-00461-4.
16.
GorterJAvan VlietEAAronicaE, et al. Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy. J Neurosci. 2006;26(43):11083-11110. doi:10.1523/JNEUROSCI.2766-06.2006.
17.
ChenZYuSBakhietMWinbladBZhuJ.The chemokine receptor CCR5 is not a necessary inflammatory mediator in kainic acid-induced hippocampal injury: evidence for a compensatory effect by increased CCR2 and CCR3. J Neurochem. 2003;86(1):61-68. doi:10.1046/j.1471-4159.2003.01807.x.
18.
ThomasAXCruz Del AngelYGonzalezMI, et al. Rapid increases in proBDNF after pilocarpine-induced status epilepticus in mice are associated with reduced proBDNF Cleavage Machinery. Eneuro. 2016;3(1):ENEURO.0020-15.2016. doi:10.1523/ENEURO.0020-15.2016.
19.
TeixeiraMMVilelaMCSorianiFMRodriguesDHTeixeiraAL.Using intravital microscopy to study the role of chemokines during infection and inflammation in the central nervous system. J Neuroimmunol. 2010;224(1-2):62-65. doi:10.1016/j.jneuroim.2010.05.018.
20.
MarksteinerJKemmlerGWeissEM, et al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging. 2011;32(3):539-540. doi:10.1016/j.neurobiolaging.2009.03.011.
21.
RentzosMNikolaouCAndreadouE, et al. Circulating interleukin-15 and RANTES chemokine in Parkinson’s disease. Acta Neurol Scand. 2007;116(6):374-379. doi:10.1111/j.1600-0404.2007.00894.x.
22.
Bartosik-PsujekHStelmasiakZ.The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. Eur J Neurol. 2005;12(1):49-54. doi:10.1111/j.1468-1331.2004.00951.x.
23.
SindernENiederkinkhausYHenschelMOssegeLMPatzoldTMalinJP.Differential release of beta-chemokines in serum and CSF of patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand. 2001;104(2):88-91. doi:10.1034/j.1600-0404.2001.104002088.x.
24.
Canouï-PoitrineFLucGMallatZ, et al. Systemic chemokine levels, coronary heart disease, and ischemic stroke events: the PRIME study. Neurology. 2011;77(12):1165-1173. doi:10.1212/WNL.0b013e31822dc7c8.
25.
LouboutinJPChekmasovaAMarusichEAgrawalLStrayerDS.Role of CCR5 and its ligands in the control of vascular inflammation and leukocyte recruitment required for acute excitotoxic seizure induction and neural damage. FASEB J. 2011;25(2):737-753. doi:10.1096/fj.10-161851.
KonkleBASchickPKHeXLiuRJMazurEM.Plasminogen activator inhibitor-1 mRNA is expressed in platelets and megakaryocytes and the megakaryoblastic cell line CHRF-288. Arterioscler Thromb. 1993;13(5):669-674. doi:10.1161/01.atv.13.5.669.
28.
MorrowGBWhyteCSMutchNJ.A serpin with a finger in many PAIs: PAI-1’s central function in thromboinflammation and cardiovascular disease. Front Cardiovasc Med. 2021;8:653655. doi:10.3389/fcvm.2021.653655.
29.
GoolaertsALafargueMSongY, et al. PAI-1 is an essential component of the pulmonary host response during Pseudomonas aeruginosa pneumonia in mice. Thorax. 2011;66(9):788-796. doi:10.1136/thx.2010.155788.
30.
LiuCZhaoXMWangQ, et al. Astrocyte-derived SerpinA3N promotes neuroinflammation and epileptic seizures by activating the NF-κB signaling pathway in mice with temporal lobe epilepsy. J Neuroinflammation. 2023;20(1):161. doi:10.1186/s12974-023-02840-8.
31.
KhanS.IGFBP-2 signaling in the brain: from brain development to higher order brain functions. Front Endocrinol (Lausanne). 2019;10:822. doi:10.3389/fendo.2019.00822.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
